U.S. Markets closed

4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)

CORAL GABLES, FL / ACCESSWIRE / January 30, 2019 / The healthcare stock market's success is largely dependent on the fact that, as the global population increases and more people need access to healthcare, companies in the space are prepared to rise to the challenge. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to showcase to the industry that Premier not only believes in future of healthcare but will be at the forefront of innovative approaches to how we treat patients.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice''s Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

Per the official details of the agreement, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million, $2 million dollars in cash to be paid out as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and $3 million payable in common shares of Premier at a deemed price of $0.76 per share.

Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, ''We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking, and other premium services with our electronic medical records (EMR) system.''

For More Information On Premier Health Group, Click Here

Co-Diagnostics Inc. (CODX), a molecular diagnostics company with a nuanced, patented platform for the development of molecular testing, announced early last week that their CoPrimer™ platform had been featured in presentations at the International Plant and Genome conference (PAG XXVII) in San Diego, California.

Following the success of the Company's presentation, Dwight Egan, CEO of Co-Diagnostics, commented, ''This product launch marks the first private label product based on the CoPrimer platform to be released on the market. We are excited for the opportunities this affords us to expand the footprint of CoPrimers to the manufacturer's international client base. As adoption of this technology helps the world become better acquainted with the many features only allowed by CoPrimers, we anticipate that Co-Diagnostics'' own brand and reputation as a developer and licensor of unique, time- and cost-saving multiplex PCR technology solutions will be enhanced.''

For More Information On Co-Diagnostics Inc., Click Here

Can-Fit BioPharma Ltd (CANF), a biotech company working to advance a pipeline of proprietary small molecule drugs that address cancer, liver, and other inflammatory diseases, today announced that a recently published article titled, ''Targeting the A3 Adenosine Receptor to Treat Cytokine Release Syndrome in Cancer Immunotherapy'' was released, detailing pertinent data from studies showing the success of one of their new drug treatments.

In a press release regarding the announcement, Dr. Pnina Fishman, Can-Fite's CEO, stated, ''While CAR-T and other cancer immunotherapies are saving lives, as their use increases, there is growing concern about the drugs'' life-threatening side effects including the high incidence of CRS. With the publication of this article in Drug Design, Development and Therapy, we are advancing the scientific community towards delivering immunotherapies that offer a high degree of efficacy with a greater degree of safety for the patient.''

For More Information on Can-Fite BioPharma Ltd, Click Here

Eyenovia Inc (EYEN), a clinical-stage ophthalmic biopharmaceutical company developing microdose therapeutics, today announced positive results from the MicroState Phase 3 MIST-1 study. Per the details of the results, the study examined the safety and efficacy of the Company's first-in-class, MicroStat fixed-combination formulation, with target markets including the estimated 80 million annual pharmacologic mydriasis market in the United States.

Dr. Sean Ianchulev, Eyenovia's Chief Executive Officer and Chief Medical Officer commented, "We are excited with the results of Phase 3 MIST-1 study. The MicroStat fixed-combination administered with the OpteJet delivered strong efficacy and was well tolerated by all subjects. We believe this is the first time in a Phase III FDA registration program that drugs have been delivered to the ocular surface using a smart microdose eyedropper-free delivery system - a meaningful step forward as we try to modernize the legacy eyedropper paradigm."

For More Information On Eyenovia Inc., Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/30/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.



SOURCE: Stock Price